This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Skye Bioscience (SKYE) announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond Phase 2 clinical trial ...

Nimacimab achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting the prominent role of peripherally-driven CB1 inhibition to induce weight loss and other ...

CB1 receptor antagonists, such as the aforementioned rimonabant and taranabant, were found to regulate food intake and adipose tissue metabolism, resulting in weight loss and favorable blood lipid ...

A member of an Arizona church admitted he molested a boy. The pastor said he knew and never went to the police, flouting ...

“He has a lot of tremendous knowledge on individual issues,” Woodhouse said. “I think his leadership and knowing how to manage and bring people together in a large legislative operation is probably ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Enter Cam Ward, the Miami Hurricanes’ signal-caller who’s making a strong case as one the top quarterback in the 2025 NFL ...

The lead candidate in the programme, INV-002, is an oral CB1 inverse agonist that has been shown to stimulate weight loss in a phase 1b trial, as well as possibly curb appetite, and has already ...